Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

37 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-19

Study Completion Date

2009-01-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine the safety and activity of MNTX in relieving opioid-induced constipation following orthopedic procedures.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Efficacy, Safety and Tolerability of Topical 2PX (Strontium Chloride Hexahydrate) in Patients With Chronic, Moderate-to-severe Lower Limb Post-amputation Stump Pain

NCT00804375

Stump Pain

UNKNOWN PHASE2

OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects

NCT00902837

Chronic Osteoarthritis

COMPLETED PHASE3

Subdermal Implant-bioabsorbable Oxandrolone Pellet For Rehabilitation Following Anterior Cruciate Ligament (ACL) Surgical Reconstruction

NCT06974526

Anterior Cruciate Ligament (ACL) Reconstruction

RECRUITING PHASE2

Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement

NCT00683267

Arthroplasty

TERMINATED PHASE2

Safety and Efficacy of Repeated Doses of PMI-150 (Intranasal Ketamine) in Acute Post-operative Pain Following Orthopedic Surgery

NCT00709436

Pain, Postoperative

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a double-blind, randomized, parallel-group, placebo- controlled Phase 2 study to evaluate the safety and activity of subcutaneous (SC) MNTX versus SC placebo in participants who have undergone orthopedic procedures and who are expected to require opioids for 1 week after randomization. Participants will sign an informed consent form and be screened between Days 4-10 after their orthopedic procedure. Those participants who meet all eligibility requirements will be enrolled in the study. Treatment with study medication will be continued until either the participant no longer requires opioid medication for pain relief or the maximum number of doses is reached. Originally, participants were receiving treatment for up to 7 days. Then after Protocol Amendment 1 (12 March 2008), the duration of treatment changed from "up to 7 days" to "up to 4 days".

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Opioid-induced Constipation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MNTX

Participants will receive methylnaltrexone (MNTX) 12 milligrams (mg) subcutaneously (SC) once daily for up to 4 or 7 days, depending upon the protocol version under which each participant is enrolled.

Group Type EXPERIMENTAL

Methylnaltrexone bromide

Intervention Type DRUG

Methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.

Placebo

Participants will receive placebo matching to MNTX SC once daily for up to 4 or 7 days, depending upon the protocol version under which each participant is enrolled.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo matching to methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Methylnaltrexone bromide

Methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.

Intervention Type DRUG

Placebo

Placebo matching to methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female participants greater than or equal to (\>=) 18 years of age.
2. Participants must have undergone an orthopedic procedure (that is, total knee or hip replacement, spinal fusion, or reduction of fracture(s) with or without surgical fixation post trauma).
3. Participants must be receiving opioid analgesics (a mu agonist only-not to include agents with mixed mechanisms of action such as tramadol or buprenorphine) after the procedures and be expected to require daily opioid analgesics for at least 7 days post randomization.
4. Participants must be acutely constipated following their orthopedic procedure.
5. Participants must receive all doses of study drug in either hospitals or rehabilitation facilities.
6. Participants must sign an informed consent form.
7. Females of childbearing potential must have a negative pregnancy test and use appropriate birth control throughout the study.
8. Body weight within range of 40 kilograms (kg) - 150 kg (88 - 330 pounds \[lbs\]).

Exclusion Criteria

1. Participants with known hypersensitivity to methylnaltrexone, naltrexone, or naloxone.
2. Participants who received any investigational new drug (experimental) in the previous 30 days.
3. Participants who have received a laxative (for example, lactulose) or an enema within 48 hours prior to the first dose.
4. Participants with constipation not attributed to post procedure opioids.
5. Participants with a history of alcohol or prescription or non-prescription drug abuse within the past 2 years.
6. Female participants who are pregnant or lactating.
7. Participants with a known history of chronic active hepatitis B or hepatitis C virus or human immunodeficiency virus (HIV) infection.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No